このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sernova 将来の成長

Future 基準チェック /06

Sernovaは、70.8%と77.5%でそれぞれ年率70.8%で利益と収益が成長すると予測される一方、EPSはgrowで61.3%年率。

主要情報

70.8%

収益成長率

63.1%

EPS成長率

Biotechs 収益成長	31.4%
収益成長率	82.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

XTRA:PSH - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
10/31/2026	0	-27	N/A	-32	3
10/31/2025	N/A	-26	-31	-30	5
10/31/2024	N/A	-31	4	-24	5
4/30/2024	N/A	-41	-27	-27	N/A
1/31/2024	N/A	-41	-29	-29	N/A
10/31/2023	N/A	-39	-30	-30	N/A
7/31/2023	N/A	-36	-24	-24	N/A
4/30/2023	N/A	-31	-24	-24	N/A
1/31/2023	N/A	-27	-18	-18	N/A
10/31/2022	N/A	-24	-15	-14	N/A
7/31/2022	N/A	-18	-12	-12	N/A
4/30/2022	N/A	-14	-9	-9	N/A
1/31/2022	N/A	-11	-8	-8	N/A
10/31/2021	N/A	-7	-7	-7	N/A
7/31/2021	N/A	-6	-6	-6	N/A
4/30/2021	N/A	-5	-6	-5	N/A
1/31/2021	N/A	-5	-5	-4	N/A
10/31/2020	N/A	-5	-5	-4	N/A
7/31/2020	N/A	-6	-6	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-4	-4	-4	N/A
7/31/2019	N/A	-3	-3	-3	N/A
4/30/2019	N/A	-3	-4	-4	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-3	N/A
4/30/2018	N/A	-3	-4	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-3	N/A
7/31/2017	N/A	-2	N/A	-3	N/A
4/30/2017	N/A	-2	N/A	-3	N/A
1/31/2017	N/A	-2	N/A	-3	N/A
10/31/2016	N/A	-2	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-2	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-3	N/A	-2	N/A
10/31/2015	N/A	-3	N/A	-2	N/A
7/31/2015	N/A	-3	N/A	-2	N/A
4/30/2015	N/A	-3	N/A	-2	N/A
1/31/2015	N/A	-3	N/A	-2	N/A
10/31/2014	N/A	-3	N/A	-2	N/A
7/31/2014	N/A	-3	N/A	-1	N/A
4/30/2014	N/A	-2	N/A	-1	N/A
1/31/2014	N/A	-2	N/A	-1	N/A
10/31/2013	N/A	-2	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PSH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PSH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSH来年は収益がないと予測されています。

高い収益成長: PSH来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PSHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Sernova 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New major risk - Share price stability

New minor risk - Market cap size

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

New minor risk - Share price stability

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘